Inflammatory bowel disease and hepatitis B and C

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 12, 2009, Pages 1082-1093

  Chevaux, J B ^a,b   Bigard, M A ^a,b   Bensenane, M ^a,b   Oussalah, A ^a,b   Jarlot, S ^a   Belle, A ^a,b   Nani, A ^a,b   Bronowicki, J P ^a,b   Peyrin Biroulet, L ^a,b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; INFLIXIMAB; LAMIVUDINE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; BLOOD TRANSFUSION; COLITIS; CROHN DISEASE; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; HEPATITIS; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PREVALENCE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SIDE EFFECT; STOMACH SURGERY; SURGICAL TECHNIQUE; ULCERATIVE COLITIS; VIRUS DETECTION; VIRUS LOAD; VIRUS REACTIVATION;

HEPATITIS B; HEPATITIS C; HUMANS; INFLAMMATORY BOWEL DISEASES; PREVALENCE;

EID: 71449100743     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.03.021     Document Type: Short Survey

References (103)

1. Prévalence des hépatites B et C en France en 2004. Institut de veille sanitaire; 2004.
2. Pillonel J., Couroucé A.M., Laporte A., and Brunet J.B. Le dépistage du VIH, de la syphilis et des hépatites B et C dans les établissements de transfusion sanguine (ETS). Bull Epidemiol Hebd 39 (1992) 185-187
3. Bronowicki J.P., Venard V., Botte C., Monhoven N., Gastin I., Chone L., et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med 337 (1997) 237-240
4. van Dullemen H.M., van Deventer S.J., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109 (1995) 129-135
5. Peyrin-Biroulet L., Deltenre P., Stalgis C., Sandborn W.J., and Colombel J.F. Achieving long-term maintenance of remission in Crohn's disease: are all anti-TNF created equal? (abstract). Gut 55 (Suppl.) (2006) A131
6. Longo F., Hebuterne X., Tran A., Staccini P., Hastier P., Schneider S., et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol 24 (2000) 77-81
7. Biancone L., Pavia M., Del Vecchio B.G., D'Inca R., Castiglione F., De Nigris F., et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 7 (2001) 287-294
8. Dubois F., Desenclos J.C., Mariotte N., and Goudeau A. Séroprévalence de l'infection par le virus C dans un échantillon national d'assurés sociaux volontaires à un examen de santé de la sécurité sociale. Bull Epidemiol Hebd 5 (1996) 17-19
9. Bargiggia S., Thorburn D., Anderloni A., Ardizzone S., Giorgi A., Bianchi P.G., et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther 22 (2005) 209-215
10. Esteve M., Saro C., Gonzalez-Huix F., Suarez F., Forne M., and Viver J.M. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53 (2004) 1363-1365
11. Loras C., Saro C., Gonzalez-Huix F., Minguez M., Merino O., Gisbert J.P., et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 104 (2009) 57-63
12. Biancone L., Del Vecchio B.G., Pallone F., Castiglione F., Bresci G., and Sturniolo G. Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology 122 (2002) 593-594
13. Colbert C., Chavarria A., and Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 13 (2007) 1453-1454
14. Laskus T., Slusarczyk J., Cianciara J., and Loch T. Exacerbation of chronic active hepatitis type B after short-term corticosteroid therapy resulting in fatal liver failure. Am J Gastroenterol 85 (1990) 1414-1417
15. Chu C.M., and Liaw Y.F. Coexpression of intercellular adhesion molecule-1 and class I major histocompatibility complex antigens on hepatocyte membrane in chronic viral hepatitis. J Clin Pathol 46 (1993) 1004-1008
16. Liaw Y.F. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 13 (1998) 14-20
17. Nagai H., Matsumaru K., Shiozawa K., Momiyama K., Wakui N., Shinohara M., et al. Disappearance of HCV after cessation of immunosuppression in a patient with ulcerative colitis and renal transplantation. J Gastroenterol 40 (2005) 848-853
18. Perrillo R.P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120 (2001) 1009-1022
19. Hui C.K., Cheung W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131 (2006) 59-68
20. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125 (2003) 1742-1749
21. Yeo W., and Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43 (2006) 209-220
22. Sagnelli E., Manzillo G., Maio G., Pasquale G., Felaco F.M., Filippini P., et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 2 (1980) 395-397
23. Tur-Kaspa R., Shaul Y., Moore D.D., Burk R.D., Okret S., Poellinger L., et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 167 (1988) 630-633
24. Scullard G.H., Smith C.I., Merigan T.C., Robinson W.S., and Gregory P.B. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81 (1981) 987-991
25. Dillon R., Hirschfield G.M., Allison M.E., and Rege K.P. Fatal reactivation of hepatitis B after chemotherapy for lymphoma (abstract). BMJ 337 (2008) A423
26. Lau G.K., Liang R., Chiu E.K., Lee C.K., and Lam S.K. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant 19 (1997) 795-799
27. Iwai K., Tashima M., Itoh M., Okazaki T., Yamamoto K., Ohno H., et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant 25 (2000) 105-108
28. Cheng A.L., Hsiung C.A., Su I.J., Chen P.J., Chang M.C., Tsao C.J., et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37 (2003) 1320-1328
29. Lok A.S., Liang R.H., Chiu E.K., Wong K.L., Chan T.K., and Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100 (1991) 182-188
30. Yeo W., Chan P.K., Zhong S., Ho W.M., Steinberg J.L., Tam J.S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62 (2000) 299-307
31. Mok M.Y., Ng W.L., Yuen M.F., Wong R.W., and Lau C.S. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 18 (2000) 363-368
32. Yang C.H., Wu T.S., and Chiu C.T. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 157 (2007) 587-590
33. Sitruk V., Fain O., Gordien E., Ganne-Carrie N., Deny P., Beaugrand M., et al. Chemotherapy and immunosuppression in patients with hepatitis B or C. Gastroenterol Clin Biol 25 (2001) 1002-1007
34. Fong T.L., Valinluck B., Govindarajan S., Charboneau F., Adkins R.H., and Redeker A.G. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 107 (1994) 196-199
35. Magy N., Cribier B., Schmitt C., Ellero B., Jaeck D., Boudjema K., et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 21 (1999) 253-261
36. Vivarelli M., Burra P., La Barba G., Canova D., Senzolo M., Cucchetti A., et al. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 47 (2007) 793-798
37. Taliani G., Tozzi A., Fanci R., Biliotti E., and Bosi A. Fatal acute hepatitis C virus infection in patients with hematological malignancies. J Chemother 18 (2006) 662-664
38. McMillan J.S., Shaw T., Angus P.W., and Locarnini S.A. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 22 (1995) 36-43
39. David-Neto E., Americo dF, Jota dP, Nahas W.C., Sabbaga E., and Ianhez L.E. The impact of azathioprine on chronic viral hepatitis in renal transplantation: a long-term, single-center, prospective study on azathioprine withdrawal. Transplantation 68 (1999) 976-980
40. Grotz W., Rasenack J., Benzing T., Berthold H., Peters T., Walter E., et al. Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin Nephrol 49 (1998) 385-388
41. Pol S., Cavalcanti R., Carnot F., Legendre C., Driss F., Chaix M.L., et al. Azathioprine hepatitis in kidney transplant recipients. A predisposing role of chronic viral hepatitis. Transplantation 61 (1996) 1774-1776
42. Stangl J.R., Carroll K.L., Illichmann M., and Striker R. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation 77 (2004) 562-567
43. Hunt J., Gordon F.D., Lewis W.D., Pomfret E., Pomposelli J.J., Jenkins R.L., et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens. Liver Transpl 7 (2001) 1056-1063
44. Melon S., Galarraga M.C., Villar M., Laures A., Boga J.A., de Ona M., et al. Hepatitis C virus reactivation in anti-hepatitic C virus-positive renal transplant recipients. Transplant Proc 37 (2005) 2083-2085
45. Laharie D., Terrebonne E., Vergniol J., Chanteloup E., Chabrun E., Couzigou P., et al. The liver and methotrexate. Gastroenterol Clin Biol 32 (2008) 134-142
46. Stange E.F., Travis S.P., Vermeire S., Beglinger C., Kupcinkas L., Geboes K., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 55 Suppl. 1 (2006) i1-15
47. Gwak G.Y., Koh K.C., and Kim H.Y. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 25 (2007) 888-889
48. El Sayed M.H., Mohamed M.M., Karim A., Maina A.M., Oliveri F., Brunetto M.R., et al. Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies. Hematol J 4 (2003) 321-327
49. Nissen M.J., Fontanges E., Allam Y., Zoulim F., Trepo C., and Miossec P. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford) 44 (2005) 1016-1020
50. Kujawska A., Clements M., Wise C.M., and Roberts W.N. Hepatitis C and methotrexate. Arthritis Rheum 49 (2003) 843-845
51. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330 (1994) 1841-1845
52. Xie H.Y., Xia W.L., Zhang C.C., Wu L.M., Ji H.F., Cheng Y., et al. Evaluation of hepatitis B virus replication and proteomic analysis of HepG2, 2. 15 cell line after cyclosporine A treatment. Acta Pharmacol Sin 28 (2007) 975-984
53. Huang C.C., Lai M.K., and Fong M.T. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation 49 (1990) 540-544
54. Bang B.K., Yang C.W., Yoon S.A., Kim Y.S., Chang Y.S., Yoon Y.S., et al. Prevalence and clinical course of hepatitis B and hepatitis C liver disease in ciclosporin-treated renal allograft recipients. Nephron 70 (1995) 397-401
55. Watashi K., Hijikata M., Hosaka M., Yamaji M., and Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38 (2003) 1282-1288
56. Heck J.A., Meng X., and Frick D.N. Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase. Biochem Pharmacol 77 7 (2009) 1173-1180
57. Yang F., Robotham J.M., Nelson H.B., Irsigler A., Kenworthy R., and Tang H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 82 (2008) 5269-5278
58. Oton E., Barcena R., Castillo M., Barreales M., Blesa C., Moreno-Planas J.M., et al. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology. Transplant Proc 38 (2006) 2499-2501
59. Antonelli A., Ferri C., Galeazzi M., Giannitti C., Manno D., Mieli-Vergani G., et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 26 Suppl. 48 (2008) S39-47
60. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
61. Ganem D., and Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
62. Carroll M.B., and Bond M.I. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38 (2008) 208-217
63. Madonia S., Orlando A., Scimeca D., Olivo M., Rossi F., and Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 13 (2007) 508-509
64. Raimondo G., Pollicino T., Cacciola I., and Squadrito G. Occult hepatitis B virus infection. J Hepatol 46 (2007) 160-170
65. Roux C.H., Brocq O., Breuil V., Albert C., and Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 45 (2006) 1294-1297
66. Zylberberg H., Rimaniol A.C., Pol S., Masson A., De Groote D., Berthelot P., et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 30 (1999) 185-191
67. Larrea E., Garcia N., Qian C., Civeira M.P., and Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 23 (1996) 210-217
68. Zein N.N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 42 (2005) 315-322
69. Cheung R.C., Currie S., Shen H., Bini E.J., Ho S.B., Anand B.S., et al. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice?. J Clin Gastroenterol 42 (2008) 827-834
70. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
71. Viget N., Vernier-Massouille G., Salmon-Ceron D., Yazdanpanah Y., and Colombel J.F. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 57 (2008) 549-558
72. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59 (2008) 762-784
73. Menter A., Gottlieb A., Feldman S.R., Van Voorhees A.S., Leonardi C.L., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58 (2008) 826-850
74. Worns M.A., Teufel A., Kanzler S., Shrestha A., Victor A., Otto G., et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol 103 (2008) 138-146
75. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
76. Khalil A., Lucidarme D., Desurmont P., Hamdan-Khalil R., and Filoche B. Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C. Gastroenterol Clin Biol 29 (2005) 193-196
77. McMahon B.J., Alward W.L., Hall D.B., Heyward W.L., Bender T.R., Francis D.P., et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 151 (1985) 599-603
78. Horvath J., and Raffanti S.P. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 18 (1994) 339-347
79. Nathan D.M., Angus P.W., and Gibson P.R. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 21 (2006) 1366-1371
80. Villa F., Rumi M.G., Signorelli C., Saibeni S., Del Ninno E., Ferrero B.S., et al. Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. Eur J Gastroenterol Hepatol 17 (2005) 1243-1245
81. Tilg H., Vogelsang H., Ludwiczek O., Lochs H., Kaser A., Colombel J.F., et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 52 (2003) 1728-1733
82. Ostuni P., Botsios C., Punzi L., Sfriso P., and Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62 (2003) 686-687
83. Michel M., Duvoux C., Hezode C., and Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 30 (2003) 1624-1625
84. Oniankitan O., Duvoux C., Challine D., Mallat A., Chevalier X., Pawlotsky J.M., et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31 (2004) 107-109
85. Valle Garcia-Sanchez M., Gomez-Camacho F., Poyato-Gonzalez A., Iglesias-Flores E.M., Dios-Vega J.F., and Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 10 (2004) 701-702
86. Wendling D., Auge B., Bettinger D., Lohse A., Le Huede G., Bresson-Hadni S., et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64 (2005) 788-789
87. Ueno Y., Tanaka S., Shimamoto M., Miyanaka Y., Hiyama T., Ito M., et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 50 (2005) 163-166
88. Anelli M.G., Torres D.D., Manno C., Scioscia C., Iannone F., Covelli M., et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 52 (2005) 2519-2520
89. Millonig G., Kern M., Ludwiczek O., Nachbaur K., and Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?. World J Gastroenterol 12 (2006) 974-976
90. Montiel P.M., Solis J.A., Chirinos J.A., Casis B., Sanchez F., and Rodriguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 28 (2008) 718-720
91. Ojiro K., Naganuma M., Ebinuma H., Kunimoto H., Tada S., Ogata H., et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 43 (2008) 397-401
92. Campbell S., and Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 13 (2001) 191-192
93. Peterson J.R., Hsu F.C., Simkin P.A., and Wener M.H. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62 (2003) 1078-1082
94. Holtmann M.H., Galle P.R., and Neurath M.F. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 98 (2003) 504-505
95. Parke F.A., and Reveille J.D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51 (2004) 800-804
96. Magliocco M.A., and Gottlieb A.B. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51 (2004) 580-584
97. De Simone C., Paradisi A., Capizzi R., Carbone A., Siciliano M., and Amerio P.L. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 54 (2006) 1102-1104
98. Rokhsar C., Rabhan N., and Cohen S.R. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 54 (2006) 361-362
99. Aslanidis S., Vassiliadis T., Pyrpasopoulou A., Douloumpakas I., and Zamboulis C. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 26 (2007) 261-264
100. Marotte H., Fontanges E., Bailly F., Zoulim F., Trepo C., and Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 46 (2007) 97-99
101. Cansu D.U., Kalifoglu T., and Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 35 (2008) 421-424
102. Ferri C., Ferraccioli G., Ferrari D., Galeazzi M., Lapadula G., Montecucco C., et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 35 (2008) 1944-1949
103. Cecchi R., and Bartoli L. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J 12 (2006) 4